Spinocerebellar ataxia type 7 (SCA7) is an inherited neurodegenerative disorder belonging to the group of spinocerebellar ataxias. This disorder is characterized by progressive ataxia, impaired motor coordination, and oculomotor dysfunction. The underlying cause of SCA7 is a genetic mutation that results in the accumulation of abnormal proteins in the brain, which in turn causes neuronal degeneration. Clinically, SCA7 presents with gait instability, speech impediments, and a variety of other neurological symptoms, such as tonic seizures and vision problems, including retinal degeneration. This disorder has a significant impact on patients’ quality of life and requires a comprehensive approach to diagnosis and treatment.
History of the disease and interesting historical facts
Spinocerebellar ataxia type 7 was first described in 1997. In the same year, the genes responsible for the disease were identified, which allowed for a deeper understanding of the pathogenesis of SCA7. One of the first researchers to study the details of this disease was a Spanish neurologist who drew attention to the common symptoms observed in patients in different families. Scientific research into this nosology continues to this day, with an emphasis on the molecular mechanisms involved in the development of the disease. In addition, SCA7 has become an object of interest for genetic research, which has allowed for the discovery of specific mutations in the ATXN7 gene, which are specific markers of this type of ataxia.
Epidemiology
The epidemiology of spinocerebellar ataxia type 7 shows that the disease is relatively rare, with an estimated prevalence of 1–9 cases per 100,000 population. The disease is seen in all regions of the world, with varying frequencies due to differences in ethnic background and genetic makeup. Higher prevalence rates have been reported in some populations, such as those with Spanish lesions, suggesting the possible influence of active mutations in certain genetic lines. Importantly, the incidence increases with age, with the first symptoms often appearing between the ages of 20 and 40.
Genetic predisposition to this disease
The pathogenesis of spinocerebellar ataxia type 7 is associated with a mutation in the ATXN7 gene, located on chromosome 3, which codes for the ataxin-7 protein. This protein contains a repeating CAG sequence, and the number of repeats varies in healthy and sick people. In healthy individuals, the number of repeats is usually from 4 to 36, while in patients with SCA7 this number can exceed 40. Genetic predisposition is the main cause of the development of this disease, and its inheritance occurs in a dominant manner, which means that it is enough for one of the parents to be a carrier of the mutation to pass the disease to the next generation.
Risk factors for the development of this disease
Risk factors that contribute to the development of spinocerebellar ataxia type 7 are primarily related to heredity. The main factors include:
- The presence of abnormal genes in the family, medical history at the family history level.
- Environmental and physical factors, such as certain chemical compounds, are sometimes considered as risk factors, although clear evidence has not been confirmed.
- Lowering the age threshold, as symptoms of the disease may appear earlier in more vulnerable younger populations.
- Comorbidities that may worsen the course of SCA7.
Diagnosis of this disease
Diagnosis of spinocerebellar ataxia type 7 is based on clinical manifestations and modern laboratory methods:
- The main symptoms include problems with balance and coordination, speech problems, and visual disturbances.
- Laboratory tests may include genetic testing for mutations in the ATXN7 gene.
- Radiological tests such as MRI can help identify characteristic changes in brain structures, including cerebellar atrophy.
- Other tests may include electroencephalography (EEG) to assess the brain's electrical activity.
- Differential diagnosis includes distinction from other forms of spinocerebellar ataxia and neurological conditions with similar symptoms, such as spindle cell disease and myasthenia gravis.
Treatment
Treatment for spinocerebellar ataxia type 7 involves several approaches:
- General treatment that aims to relieve symptoms and improve the patient's quality of life.
- Pharmacological treatment may include medications to control symptoms, such as anticonvulsants and antidepressants.
- Surgical treatment is rarely used, but may be justified in cases of severe disorders requiring intervention.
- Other treatments include physical therapy and speech therapy to improve movement and alleviate speech impairments.
List of medications used to treat this disease
Classification of pharmacological treatment for SCA7 may include:
- Anticonvulsants (eg, carbamazepine).
- Antidepressants (such as sertraline).
- Neuroprotectors (eg, memantine).
- Medicines to improve blood circulation in the brain (eg, piracetam).
Disease monitoring
Monitoring of patients with spinocerebellar ataxia type 7 includes regular check-ups to assess disease progression. Prognosis depends on the individual characteristics of the disease course, timing of seeking medical care and initiation of treatment. Potential complications include loss of independence and development of comorbid conditions such as depression and social isolation.
Age-related features of the disease
Spinocerebellar ataxia type 7 can manifest itself in both young and old age, but the first symptoms most often appear between the ages of 20 and 40. In older patients, the course of the disease may be more pronounced, with a higher chance of developing complex concomitant diseases. In children and adolescents, the disease also has its own characteristics: it can change depending on the stage of growth and development of the nervous system.
Questions and Answers
- What are the main symptoms of SCA7? The main symptoms of SCA7 include progressive ataxia, impaired motor coordination, visual impairment, and speech impairment.
- How is the disease diagnosed? Diagnosis includes clinical examination, genetic testing, MRI and other methods such as EEG.
- Can SCA7 be cured? There is currently no cure for SCA7, but there are treatments that can help control symptoms and improve quality of life.
- What is the heredity of the disease? Spinocerebellar ataxia type 7 is inherited in a dominant manner, meaning that one parent only needs to be a carrier of the mutation.
- What is the outlook for SCA7 patients? The prognosis depends on many factors, including the age at which the disease begins and the rate of progression, as well as the quality of treatment.
